Macrogenics
$3.57
39
+$0.09+2.74% Today
Statistics
Day High
3.61
Day Low
3.5
52W High
3.88
52W Low
1.1
Volume
215,472
Avg. Volume
1,118,168
Mkt Cap
225.52M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
13MayExpected
Expected EPS
-0.565
Actual EPS
N/A
Financials
-44.66%Profit Margin
Unprofitable299.92MRevenue
-133.93MNet Income
Analyst Ratings
5Average Price Target
The highest estimate is 9.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 67%
Hold 33%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow MGNX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap19.12B
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
AMGEN
AMGN
Mkt Cap189.22B
Gilead Sciences
GILD
Mkt Cap172.51B
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Pfizer
PFE
Mkt Cap153.13B
Novartis
NVS
Mkt Cap297.35B
About
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Show more...
CEO
Mr. Jeffrey Stuart Peters J.D.
Employees
341
Country
United States
ISIN
US5560991094
Listings
0 Comments
Share your thoughts
FAQ
What is Macrogenics stock price today?▼
The current price of MGNX is $3.57 USD — it has increased by +2.74% in the past 24 hours. Watch Macrogenics stock price performance more closely on the chart.
What is Macrogenics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Macrogenics stocks are traded under the ticker MGNX.
Is Macrogenics stock price growing?▼
MGNX stock has risen by +5.82% compared to the previous week, the month change is a +18.17% rise, over the last year Macrogenics has showed a +179.13% increase.
What is Macrogenics market cap?▼
Today Macrogenics has the market capitalization of 225.52M
When is the next Macrogenics earnings date?▼
Macrogenics is going to release the next earnings report on May 13, 2026.
What were Macrogenics earnings last quarter?▼
MGNX earnings for the last quarter are -0.23 USD per share, whereas the estimation was -0.12 USD resulting in a -89.56% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Macrogenics revenue for the last year?▼
Macrogenics revenue for the last year amounts to 299.92M USD.
What is Macrogenics net income for the last year?▼
MGNX net income for the last year is -133.93M USD.
How many employees does Macrogenics have?▼
As of April 14, 2026, the company has 341 employees.
In which sector is Macrogenics located?▼
Macrogenics operates in the Health & Wellness sector.
When did Macrogenics complete a stock split?▼
Macrogenics has not had any recent stock splits.
Where is Macrogenics headquartered?▼
Macrogenics is headquartered in Rockville, United States.